CHALLENGES AND FUTURE PROSPECTS OF ONCOLYTIC VIROTHERAPY: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.71000/2zmn9925Keywords:
Cancer therapy, Oncolytic viruses, Virotherapy, , Challenges, Personalized medicine, Tumor immunity, Viral vectors.Abstract
Background: Oncolytic virotherapy has emerged as a novel and promising approach in cancer treatment, leveraging viruses that selectively infect and destroy malignant cells while sparing healthy tissues. Recent advancements in molecular biology and virology have enabled the development of genetically engineered viruses with enhanced tumor specificity, immune-stimulatory capacity, and safety profiles. As resistance to conventional therapies continues to pose a major clinical challenge, oncolytic viruses (OVs) offer a dual mechanism of action—direct tumor lysis and activation of antitumor immunity—placing them at the forefront of experimental oncology.
Objective: To analyze the challenges and future prospects associated with oncolytic virotherapy as a targeted cancer treatment strategy.
Methods: A systematic review was conducted using Google Scholar and PubMed databases. A total of 118 studies were initially identified. After applying inclusion and exclusion criteria, 28 full-text, peer-reviewed articles published between 2010 and 2025 were included. Data were extracted into structured tables summarizing study design, mechanisms of action, combination therapy strategies, challenges, and future directions of oncolytic virotherapy. A risk of bias assessment was also performed to evaluate study quality.
Results: Among the 28 studies reviewed, 60% were preclinical experimental models and 40% were clinical trials. Genetic engineering was reported to significantly enhance viral specificity, safety, and immune activation. Advanced delivery systems, including nanoparticles and cell carriers, showed improved targeting and persistence. However, major limitations included immune clearance, suppressive tumor microenvironments, and systemic delivery challenges. T-VEC remains the only FDA-approved OV, but newer candidates like CVA21 and BTV-10 show promise in early trials.
Conclusion: Oncolytic virotherapy represents a rapidly evolving cancer treatment modality with significant therapeutic potential. Overcoming delivery and immunological challenges through personalized and combination-based approaches may establish OVs as a core component of future oncology practice.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers (Basel). 2021;13(21).
Peter M, Kühnel F. Oncolytic adenovirus in cancer immunotherapy. Cancers (Basel). 2020;12(11):1–23.
Luo D, Wang H, Wang Q, Liang W, Liu B, Xue D, et al. Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions. Front Oncol. 2022;12(March):1–13.
Chaurasiya S, Fong Y, Warner SG. Oncolytic virotherapy for cancer: Clinical experience. Biomedicines. 2021;9(4).
Chen L, Zuo M, Zhou Q, Wang Y. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front Immunol. 2023;14(December):1–14.
Yang M, Olaoba OT, Zhang C, Kimchi ET, Staveley-O’Carroll KF, Li G. Cancer Immunotherapy and Delivery System: An Update. Pharmaceutics. 2022;14(8):1–27.
Li H, Zeng Z, Fu X, Zhang X. Coadministration of a herpes simplex virus-2-based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res. 2007;67(16):7850–5.
Zhang S, Rabkin SD. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? Expert Opin Drug Discov. 2021;16(4):391–410.
Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective. Oxid Med Cell Longev. 2022;2022.
Boagni DA, Ravirala D, Zhang SX. Current strategies in engaging oncolytic viruses with antitumor immunity. Mol Ther Oncolytics. 2021;22(September):98–113.
Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7(1).
Mashima H, Zhang R, Kobayashi T, Hagiya Y, Tsukamoto H, Liu T, et al. Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response. Oncoimmunology [Internet]. 2020;9(1).
Kulbay M, Tuli N, Mazza M, Jaffer A, Juntipwong S, Marcotte E, et al. Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances. Biomedicines. 2025;13(1):1–38.
Fujiwara T. Multidisciplinary oncolytic virotherapy for gastrointestinal cancer. Ann Gastroenterol Surg. 2019;3(4):396–404.
Li L, Liu S, Han D, Tang B, Ma J. Delivery and Biosafety of Oncolytic Virotherapy. Front Oncol. 2020;10(April):1–15.
Wang L, Chard Dunmall LS, Cheng Z, Wang Y. Remodeling the tumor microenvironment by oncolytic viruses: Beyond oncolysis of tumor cells for cancer treatment. J Immunother Cancer. 2022;10(5).
Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: Hopes and hurdles. Adv Virol. 2012;2012.
Hamidi-Sofiani V, Rakhshi R, Moradi N, Zeynali P, Nakhaie M, Behboudi E. Oncolytic viruses and pancreatic cancer. Cancer Treat Res Commun [Internet]. 2022;31(April):100563.
Goradel NH, Baker AT, Arashkia A, Ebrahimi N, Ghorghanlu S, Negahdari B. Oncolytic virotherapy: Challenges and solutions. Curr Probl Cancer [Internet]. 2021;45(1):100639.
Yokoda R, Nagalo B, Vernon B, Oklu R, Albadawi H, DeLeon T, et al. Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. Oncolytic Virotherapy. 2017; Volume 6:39–49.
Zhao JL, Lin BL, Luo C, Yi YL, Huang P, Chen Y, et al. Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis. J Transl Med [Internet]. 2024;22(1):1000.
Xu G, Xu S, Shi X, Shen C, Hao J, Yan M, et al. Intercellular transmission of Seneca Valley virus mediated by exosomes. Vet Res [Internet]. 2020;51(1):1–10.
Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, et al. Oncolytic viruses in combination therapeutic approaches with epigenetic modulators: Past, present, and future perspectives. Cancers (Basel). 2021;13(11).
Bai Y, Hui P, Du X, Su X. Updates to the antitumor mechanism of oncolytic virus. Thorac Cancer. 2019;10(5):1031–5.
Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccines Immunother [Internet]. 2020;16(10):2389–402.
Zhu X, Fan C, Xiong Z, Chen M, Li Z, Tao T, et al. Development and application of oncolytic viruses as the nemesis of tumor cells. Front Microbiol. 2023;14(June):1–21.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell [Internet]. 2011;144(5):646–74.
Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Tahseen Javaid Shah, Sana Yousuf, Muhammad Arslan, Aqsa Naaz, Sehrish Gull, Zainab Ali, Muhammad Sulaiman Saeed (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
